NASDAQ:TENX
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc.'s revenue was $0 in fiscal 2025. The diluted share count rose 156.8%.Summary generated from Tenax Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−55.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+156.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 0 | 0 |
| Operating income | −33 | 11 | −8 | −19 | −56 |
| Net income | −32 | 11 | −8 | −18 | −53 |
| Free cash flow | −11 | −11 | n/a | n/a | n/a |
Recent filings
- 8-KOther events
Oct 8, 2026 - 4Insider transaction report
Sep 17, 2026 - 4Insider transaction report
Sep 15, 2026 - 8-KRegulation FD disclosure
Sep 9, 2026 - 8-KOther events
Aug 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 31, 2026 - 8-KResults of operations and financial condition
Jul 31, 2026 - 8-KOther events
Jul 2, 2026